MedPath

Tiragolumab

Generic Name
Tiragolumab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
1918185-84-8
Unique Ingredient Identifier
6XG22YQM2Z
Background

Tiragolumab is under investigation in clinical trial NCT04513925 (A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)).

Associated Conditions
-
Associated Therapies
-
cancernetwork.com
·

Tiragolumab/Atezolizumab Does Not Meet OS End Point in Metastatic NSCLC

Tiragolumab with atezolizumab failed to improve overall survival in PD-L1–high, locally advanced or metastatic NSCLC patients compared to atezolizumab alone in the SKYSCRAPER-01 study. No new safety signals were identified, and more data will be presented in 2025.
healio.com
·

Phase 3 lung cancer trial misses survival endpoint

Phase 3 trial of tiragolumab plus atezolizumab for advanced lung cancer failed to meet OS endpoint.
stocktitan.net
·

Roche reports update on Phase III SKYSCRAPER-01 study results

Roche's phase III SKYSCRAPER-01 study, evaluating tiragolumab plus Tecentriq versus Tecentriq alone in PD-L1-high NSCLC patients, did not meet its primary endpoint of overall survival. The study involved 534 previously untreated, locally advanced unresectable or metastatic NSCLC patients. Safety profile remained consistent with no new safety signals. Detailed data to be presented at a medical meeting in 2025.
stocktitan.net
·

Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results

Genentech's Phase III SKYSCRAPER-01 study, testing tiragolumab + Tecentriq vs. Tecentriq alone in PD-L1-high NSCLC, did not meet its primary endpoint of overall survival. The study involved 534 previously untreated patients with locally advanced unresectable or metastatic NSCLC. Safety profile remained consistent, with no new signals identified; detailed data to be presented in 2025.
drugs.com
·

Genentech Reports Update on Phase III SKYSCRAPER-01 Study Evaluating Tiragolumab Combined with Tecentriq

Genentech reports Phase III SKYSCRAPER-01 study did not meet primary endpoint of overall survival for tiragolumab plus Tecentriq vs. Tecentriq alone in PD-L1-high NSCLC patients. Safety profile remained consistent with no new signals. Data to be presented in 2025.
pharmexec.com
·

Leverage AI to Lower Cost, Barriers to Cell Therapies

Cell therapy is evolving from autologous to allogeneic, aiming for ready-made treatments. Challenges include immune rejection and costly clinical trials. AI could predict optimal cell combinations, but FDA approval processes need modernization for broader access. Off-the-shelf therapies promise affordability and accessibility, potentially revolutionizing precision medicine.
biospace.com
·

TIGITs Trend Upward After iTeos/GSK Present Positive Data at ESMO

Recent Phase II data from iTeos and GSK's anti-TIGIT therapy belrestotug plus anti-PD-1 Jemperli shows promising response rates in NSCLC patients, despite high-profile failures in the TIGIT space. Despite setbacks, companies like Roche and Merck continue TIGIT studies, emphasizing trial design's impact on outcomes. Insights suggest anti-TIGIT therapy may benefit patients with high CD-155 expression, potentially as combination therapy. Recent positive results from iTeos/GSK and Gilead/Arcus indicate a possible turning tide in TIGIT therapeutics.
© Copyright 2025. All Rights Reserved by MedPath